Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short-term Investments (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Short-term Investments over the past 6 years, most recently at $1.5 million for Q4 2018.

  • For Q4 2018, Short-term Investments rose 66.34% year-over-year to $1.5 million; the TTM value through Nov 2018 reached $1.5 million, up 66.34%, while the annual FY2018 figure was $1.5 million, 122.24% up from the prior year.
  • Short-term Investments for Q4 2018 was $1.5 million at Lifecore Biomedical, Inc. \De\, up from $1.5 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $1.5 million in Q2 2018 and troughed at $519000.0 in Q4 2016.
  • A 3-year average of $1.0 million and a median of $909000.0 in 2017 define the central range for Short-term Investments.
  • On a YoY basis, Short-term Investments climbed as much as 177.65% in 2018 and fell as far as 66.34% in 2018.
  • Year by year, Short-term Investments stood at $519000.0 in 2016, then skyrocketed by 75.14% to $909000.0 in 2017, then soared by 66.34% to $1.5 million in 2018.
  • Business Quant data shows Short-term Investments for LFCR at $1.5 million in Q4 2018, $1.5 million in Q3 2018, and $1.5 million in Q2 2018.